View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsCrescita Therapeutics 将来の成長Future 基準チェック /06現在、 Crescita Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Crescita Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:CRRT.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202623012N/A12/31/202521001N/A9/30/202522012N/A6/30/202520-101N/A3/31/202518-302N/A12/31/202420-313N/A9/30/202417-3-11N/A6/30/202417-301N/A3/31/202418-200N/A12/31/202318-222N/A9/30/202319-100N/A6/30/202322100N/A3/31/202323100N/A12/31/2022241-1-1N/A9/30/202225101N/A6/30/202222000N/A3/31/202218-1-1-1N/A12/31/202117-1-2-2N/A9/30/202112-3-1-1N/A6/30/202116244N/A3/31/202115055N/A12/31/202016066N/A9/30/202017055N/A6/30/202014-422N/A3/31/202022133N/A12/31/2019222N/A5N/A9/30/2019255N/A6N/A6/30/2019246N/A3N/A3/31/2019173N/A2N/A12/31/2018172N/A-1N/A9/30/201813-9N/A-4N/A6/30/201811-10N/A-4N/A3/31/201814-9N/A-5N/A12/31/201712-11N/A-7N/A9/30/201712-8N/A-11N/A6/30/201710-10N/A-13N/A3/31/20175-13N/A-15N/A12/31/20164-15N/A-19N/A9/30/20161-12N/A-16N/A6/30/20160-7N/A-15N/A3/31/20160-10N/A-18N/A12/31/20150-7N/A-14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CRRT.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CRRT.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CRRT.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CRRT.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CRRT.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CRRT.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/03 11:48終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Crescita Therapeutics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.
お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.
お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.
お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024.